Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative

Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients. Improving outcomes even further in this patient population will require a multi-disciplinary approach, including pre-clinical and translational studies, clinical trials, and studies of patient reported outcomes and quality of life. At the 2023 and 2024 joint Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) CNS Metastases Conferences, two ICM collaborative group think tanks convened, composed of diverse, multi-disciplinary stakeholders, including basic and translational researchers, clinical trialists, and clinicians from academia and the community setting. Here we summarize the key knowledge gaps and consensus recommendations put forth by these two think tanks. Advances in ICM research and improvements in patient outcomes will require close inter-specialty and inter-institutional collaboration between stakeholders, including pre-clinical and translational researchers, clinical investigators, industry, and regulatory bodies.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-09-30
DOI
https://doi.org/10.1093/neuonc/noaf226
Citations
1
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative

Michelle M. Kim, Rachna Malani, Mustafa Khasraw, Akanksha Sharma et al.
1 citations
Neuro-Oncology
Brain Metastases and Treatment
1.52
article

Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative

Michelle M. Kim, Rachna Malani, Mustafa Khasraw, Akanksha Sharma, Amanda E.D. Van Swearingen, Stephen Bagley, Mariza Daras, Diana M. Cittelly, Carey K. Anders, Jona A. Hattangadi‐Gluth, Josh Neman, Solmaz Sahebjam, Peter E. Fecci, Sarah B. Goldberg, Saul J. Priceman, Manmeet S. Ahluwalia, Minesh P. Mehta, Lucy Boyce Kennedy, Don X. Nguyen, Helen Alice Shih, Michael A. Davies, Nancy U. Lin, Katarzyna J. Jerzak, Veronica Chiang, Nelson S. Moss, Daphne Adele Haas-Kogan, Riccardo Soffietti, Nancy Wang, Alexandra Dos Santos Zimmer
article en
1 citations

Abstract

Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients. Improving outcomes even further in this patient population will require a multi-disciplinary approach, including pre-clinical and translational studies, clinical trials, and studies of patient reported outcomes and quality of life. At the 2023 and 2024 joint Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) CNS Metastases Conferences, two ICM collaborative group think tanks convened, composed of diverse, multi-disciplinary stakeholders, including basic and translational researchers, clinical trialists, and clinicians from academia and the community setting. Here we summarize the key knowledge gaps and consensus recommendations put forth by these two think tanks. Advances in ICM research and improvements in patient outcomes will require close inter-specialty and inter-institutional collaboration between stakeholders, including pre-clinical and translational researchers, clinical investigators, industry, and regulatory bodies.

Neuro-OncologyVol. 28(2)
University of Southern California (US), Baptist Hospital of Miami (US), Cleveland Clinic (US), Sunnybrook Health Science Centre (CA), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Johns Hopkins University (US), Oregon Health & Science University (US), Virginia Commonwealth University (US), University of Michigan (US), Johns Hopkins Medicine (US), Huntsman Cancer Institute (US), California Pacific Medical Center (US), Yale Cancer Center (US), University of California System (US), Yale University (US), University of California San Diego (US), Massachusetts General Hospital (US), Harvard Affiliated Emergency Medicine Residency (US), Baptist Health South Florida (US), Parker Institute for Cancer Immunotherapy (US), Michigan Medicine (US), Dana-Farber Cancer Institute (US), Duke Medical Center (US), Candiolo Cancer Institute (IT), University of Colorado Anschutz Medical Campus (US), University of Pennsylvania (US)
Pfizer, American Society of Clinical Oncology, Regeneron Pharmaceuticals, Novocure, Incyte, Apollomics, EpicentRx, Servier
Openalex Percentile: Top 14%
Brain Metastases and Treatment
1.52
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.